These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 33820953)

  • 41. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advances in immunotherapy for prostate cancer.
    Markiewicz MA; Kast WM
    Adv Cancer Res; 2003; 87():159-94. PubMed ID: 12641276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
    Chesney JA; Mitchell RA; Yaddanapudi K
    J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Impact of High Intensity Focused Ultrasound (HIFU) on Tumor-Specific Immune Responses of Prostate Cancer.
    Chen W; He L; Huang H; Zeng X; Fu G; Liu Y; Liang Y
    Arch Esp Urol; 2024 May; 77(4):322-330. PubMed ID: 38840273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
    Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR
    Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
    Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
    Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
    Jindal V
    Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment.
    Wallecha A; Singh R; Malinina I
    J Immunother; 2013; 36(9):468-76. PubMed ID: 24145358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
    Shen L; Sundstedt A; Ciesielski M; Miles KM; Celander M; Adelaiye R; Orillion A; Ciamporcero E; Ramakrishnan S; Ellis L; Fenstermaker R; Abrams SI; Eriksson H; Leanderson T; Olsson A; Pili R
    Cancer Immunol Res; 2015 Feb; 3(2):136-48. PubMed ID: 25370534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
    Bou-Dargham MJ; Sha L; Sang QA; Zhang J
    BMC Cancer; 2020 Jun; 20(1):572. PubMed ID: 32552802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force.
    Hatziioannou A; Alissafi T; Verginis P
    J Leukoc Biol; 2017 Aug; 102(2):407-421. PubMed ID: 28360184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The evolving role of immunotherapy in prostate cancer.
    Cordes LM; Gulley JL; Madan RA
    Curr Opin Oncol; 2016 May; 28(3):232-40. PubMed ID: 26977847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
    Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
    J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.
    Melo CM; Vidotto T; Chaves LP; Lautert-Dutra W; Reis RBD; Squire JA
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
    Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
    Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.